AstraZeneca Partners With AmoyDx On Companion Diagnostics For Lynparza
Executive Summary
Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.
You may also be interested in...
FDA Approves Foundation Medicine Liquid Biopsy Test As Companion Diagnostic For Lynparza
The US FDA expanded the use of FoundationOne Liquid CDx as a companion diagnostic for certain prostate cancer patients eligible for treatment with olaparib.
AZ/Merck & Co' s Lynparza Gets US Approval For Prostate Cancer
Lynparza has received the green light from the FDA for advanced prostate cancer, its fourth tumor type, and while it may not be the first PARP inhibitor to be approved for this indication, analysts are expecting the drug to lead the class.
Sanofi Looks To Atomwise For More AI Help
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.